Prescribing Recommendations for the Treatment of Acute Pain in Dentistry

By Elliot V. Hersh, DMD, MS, PhD; William T. Kane, DDS, MBA; Michael G. O’Neil, PharmD; George A. Kenna, PhD, RPh; Nathaniel P. Katz, MD; Stephanie Golubic, DMD, MBE; and Paul A. Moore, DMD, PhD, MPH

LEARNING OBJECTIVES

• compare the relative efficacy of several common oral analgesics used to manage acute pain in dentistry.
• employ an analgesic-prescribing paradigm based on the anticipated severity of post-procedural pain and patient characteristics.
• consider additional methods to reduce patients’ need for postoperative analgesics.
• educate patients to safeguard drugs with abuse liability and dispose of them appropriately when no longer required.

ABSTRACT

Effective acute pain management is an essential but sometimes challenging component of dental practice. Numerous studies have examined the efficacy of various analgesic agents in dental postoperative models. This article combines an evaluation of the available evidence with current prescribing patterns to provide dental practitioners prescribing recommendations for acute pain, based on the anticipated severity of post-procedural pain. An important consideration when prescribing analgesics is to determine for whom opioid analgesics are necessary and appropriate, and if so, the dose and quantity that should be prescribed. This is partly because of the prevalence of substance and alcohol abuse that can be expected to be encountered within the dental patient population, and because substance abusers in the community frequently obtain prescription drugs from friends and family for misuse.
A number of dental procedures cause acute postprocedural pain, making effective pain management for all patients an essential component of dental practice. Achieving adequate and safe pain relief may be more challenging in some patient populations, such as those with substance abuse or chronic pain disorders. However, pain following certain dental procedures can be anticipated, which provides dentists an opportunity to thoughtfully plan and optimize the management of acute pain.

**OVERVIEW OF EVIDENCE FOR ANALGESIC USE IN DENTAL PAIN**

Postoperative pain following the surgical removal of impacted third molars is a frequently used analgesic model because of the consistency and intensity of the postoperative pain. This common procedure is performed under local anesthesia, usually with concomitant intravenous-consious sedation or short-acting general anesthesia. The trauma to soft tissue and the maxillary and mandibular alveolar bone results in release of inflammatory and algic mediators at the peripheral surgical sites. Predictably, 3 to 4 hours after surgery, 95% or more of individuals have moderate to severe pain that in clinical trials can be used to distinguish active drugs from placebo, and also detect differences between moderately effective and highly effective analgesics. In addition, these are relatively healthy patients who are not on confounding medications, with an average age of 20 years. Therefore, this model is common in pivotal double-blind, randomized, placebo-controlled trials for US Food and Drug Administration (FDA) approval of analgesics.

Several early oral surgery analgesic studies have assessed peripherally acting analgesics. Both aspirin 650 mg and acetaminophen (APAP) 650 mg produced significantly better pain-relief scores than placebo, with approximate equal analgesia. APAP and aspirin have linear dose-response curves with a ceiling effect thought to be in the neighborhood of 1,000 mg. The maximum daily doses of APAP and aspirin should not exceed 4,000 mg, and lower doses might often deliver adequate analgesia with a lower risk of rare but serious adverse events. When calculating total daily doses, it is important to appreciate that opioid combination products and over-the-counter (OTC) medications may contain APAP or aspirin. To go beyond the analgesic effects of maximum doses of aspirin or APAP, an optimal or near-optimal dose of aspirin or APAP can be combined with a centrally acting opioid (such as oxycodone 5 mg, hydrocodone 10 mg, codeine 60 mg, or tramadol 75 mg). In several studies, an opioid alone produced similar or inferior postoperative pain relief to aspirin or APAP alone. However, combining an opioid with aspirin or APAP produced an additive analgesic effect, which is consistent with opioids producing analgesia by a mechanism different from the peripherally acting agents. Because many combination formulations contain less than optimal doses of the peripherally acting component, underdosing of these agents is common. For example, a single tablet of the strengths of Percocet (APAP 325 mg/oxycodone 5 mg tablets) contains only 325 mg of APAP. The optimal doses of aspirin or APAP to prescribe when using these combination products has been reported to be 600 mg to 1,000 mg. Increasing the number of doses of combination products to achieve higher aspirin or APAP doses also increases the opioid dose. So while the increased doses tends to be more efficacious, they also induce a higher incidence of opioid-related side effects.

The newer nonsteroidal anti-inflammatory drugs (NSAIDs) at the upper end of their dose-response curve appear significantly more efficacious than APAP or aspirin 650 mg to 1,000 mg. In the United States, the current gold-standard analgesic in moderate to severe postoperative dental pain is ibuprofen 400 mg, which is as effective as codeine 60 mg with aspirin 650 mg. There are too few studies to demonstrate a definitive advantage of ibuprofen 600 mg or 800 mg over 400 mg in acute postoperative dental pain, and one study found no difference in analgesic effectiveness between ibuprofen 400 mg and 800 mg. Similarly to the early studies of APAP and aspirin in postoperative dental pain, ibuprofen 400 mg alone is a more effective analgesic than single-entity morphine 60 mg, oxycodone 5 mg, and the novel, centrally acting analgesic tapentadol at 50-mg, 75-mg, and 100-mg dosage strengths. It is thought that the anti-inflammatory and analgesic properties of NSAIDs (and most of their side effects) result from their inhibition of cyclooxygenase (COX)—a key enzyme in the production of postoperative pain and inflammation due to its ability to convert arachidonic acid to prostaglandins. Aspirin is unique in inactivating COX by irreversible acetylation, whereas the newer NSAIDs are reversible competitive inhibitors of COX. A number of NSAIDs are available in the United States, which do differ in terms of potential for gastrointestinal (GI) toxicity (ibuprofen demonstrates the lowest relative risk) and platelet inactivation.

Ibuprofen 400 mg combined with an opioid has a faster onset of effect and greater peak effects than ibuprofen 400 mg alone. Pain relief with oxycodone 5 mg/ibuprofen 400 mg is superior to that achieved with oxycodone 5 mg/APAP 325 mg or hydrocodone 7.5 mg/APAP 500 mg. Due to their different mechanisms of action, there is also an emerging compilation of study data which supports the strategy of combining an NSAID with APAP to provide analgesia greater than either APAP or the NSAID alone. A recently published systematic review reported that...
the combination of an NSAID plus APAP provided pain relief greater than the NSAID alone in 9 of 14 postoperative pain studies.25 With respect to postoperative dental pain, five of six studies showed reduced pain intensity and increased pain relief with the combination than the NSAID alone.24-29 In the dental pain studies that displayed analgesic enhancement, APAP 500 mg to 1,000 mg was combined with the NSAID.24,26-29

OTHER THERAPEUTIC APPROACHES

Pre-emptive NSAIDs

Studies have demonstrated that preoperative administration of ibuprofen delays the onset of pain (by more than 100 minutes compared with placebo) and lessened the severity of postoperative dental pain as the effect of the local anesthetic dissipated, without increased side effects.30,31 The beneficial effects of pre-emptive NSAID use is further illustrated by a study that showed that preoperative and postoperative administration of flurbiprofen achieved superior pain relief than APAP alone or in combination with oxycodone.32 This data supports the clinical strategy of administering an NSAID an hour before or immediately after the surgical procedure, and then dosing the NSAID on a fixed around-the-clock schedule for the first 24 to 48 hours. Preoperative dosing of NSAIDs is often avoided by dentists because of concerns that increased bleeding will result. While the amount of bleeding was not directly measured, the preoperative administration of a single dose of ibuprofen 400 mg or flurbiprofen 50 mg to 100 mg did not result in any significant increase in intraoperative or postoperative bleeding.30-32 Short-term use of ibuprofen in particular has been shown to only marginally reduce platelet aggregation compared to other NSAIDs such as ketoprofen or aspirin.33,34

Postoperative Long-Acting Local Anesthetic

Another therapeutic approach to attenuate postoperative pain is the administration of the long-acting local anesthetic, bupivacaine 0.5% with 1:200,000 epinephrine, during the immediate postoperative period.35,36 Patients who had third molar extractions under general anesthesia were randomized to one of four groups: preoperative lidocaine 2% with 1:100,000 epinephrine, postoperative bupivacaine 0.5% with 1:200,000 epinephrine, both, or placebo injections.36 In the bupivacaine groups, pain was not only diminished in the immediate postoperative period (0 to 4 hours), but also 48 hours after surgery compared with placebo and lidocaine alone.36 This strategy is most effective if combined with pre-emptive and around-the-clock NSAIDs during the immediate postoperative period.

RELATIVE EFFICACY OF ORAL ANALGESICS: SYNTHESIS OF EVIDENCE

A meta-analysis of randomized, double-blind studies of analgesics for acute pain after third molar extraction compared the relative efficacy of a single dose of several oral analgesics.27 The number of patients with moderate or severe pain achieving at least 50% maximum pain relief over 4 to 6 hours was used to calculate the number needed to treat (NNT) with active drug to get one additional patient with at least 50% pain relief compared with placebo (Figure 1) (the lower the NNT, the more effective the analgesic).27 Single-dose diclofenac 100 mg had the lowest NNT.
Most of the available data on dentists’ analgesic prescribing practices focus on oral surgeons. Recently, a statewide survey conducted in West Virginia evaluated dentists’ analgesic prescribing patterns with an emphasis on opioids, and experiences with patient drug diversion and substance abuse.39 Data from 52% of all dentists in West Virginia (mainly general dental practitioners), showed that the most frequently prescribed analgesic if no opioids were prescribed was NSAIDs (64%), followed by APAP (28%).39 The most prescribed opioid was hydrocodone/APAP (73%).39 The amount of opioids given after third molar extraction varied greatly, but 20 doses and a 3-day supply was most common. The pattern of days of therapy for the most common opioids prescribed was similar following root canal.39

The question raised by these two studies is whether 20 tablets of an opioid/APAP combination agent is an appropriate amount after third molar extraction and what happens to unused opioids, if anything. Addressing the first part of the question, there is not a large amount of data about the number of days that dental patients are in pain after the procedure—but some studies provide an indication. In a study of dental impaction surgery causing moderate to severe pain, patients typically took NSAIDs (ibuprofen or meclofenamate) for between 4 and 6 days.18 After dental implant surgery, the typical dosing period with APAP/hydrocodone was between 2 and 3 days.40 However, there needs to be flexibility in the number of days supply, because some people will legitimately need analgesics for 6 or 7 days, with 24% in one study still taking analgesics on postoperative day 10 after removal of four third molars.8

The question raised by these two studies is whether 20 tablets of an opioid/APAP combination agent is an appropriate amount after third molar extraction and what happens to unused opioids, if anything. Addressing the first part of the question, there is not a large amount of data about the number of days that dental patients are in pain after the procedure—but some studies provide an indication. In a study of dental impaction surgery causing moderate to severe pain, patients typically took NSAIDs (ibuprofen or meclofenamate) for between 4 and 6 days.18 After dental implant surgery, the typical dosing period with APAP/hydrocodone was between 2 and 3 days.40 However, there needs to be flexibility in the number of days supply, because some people will legitimately need analgesics for 6 or 7 days, with 24% in one study still taking analgesics on postoperative day 10 after removal of four third molars.8

**CURRENT PRACTICE PATTERNS**

A survey of dental prescribing practices among oral surgeons after third molar extraction found that the preferred peripherally acting postoperative analgesic is ibuprofen (73.5%), but 85% of oral surgeons also almost always prescribe a centrally acting opioid analgesic, with the drug of choice being hydrocodone/APAP (64%).1 On average, 20 tablets of hydrocodone/APAP are prescribed, with instructions in 96% of cases to “take as needed for pain.”

Most of the available data on dentists’ analgesic prescribing practices focus on oral surgeons. Recently, a statewide survey conducted in West Virginia evaluated dentists’ analgesic prescribing patterns with an emphasis on opioids, and experiences with patient drug diversion and substance abuse.39 Data from 52% of all dentists in West Virginia (mainly general dental practitioners), showed that the most frequently prescribed analgesic if no opioids were prescribed was NSAIDs (64%), followed by APAP (28%).39 The most prescribed opioid was hydrocodone/APAP (73%).39 The amount of opioids given after third molar extraction varied greatly, but 20 doses and a 3-day supply was most common. The pattern of days of therapy for the most common opioids prescribed was similar following root canal.39

The question raised by these two studies is whether 20 tablets of an opioid/APAP combination agent is an appropriate amount after third molar extraction and what happens to unused opioids, if anything. Addressing the first part of the question, there is not a large amount of data about the number of days that dental patients are in pain after the procedure—but some studies provide an indication. In a study of dental impaction surgery causing moderate to severe pain, patients typically took NSAIDs (ibuprofen or meclofenamate) for between 4 and 6 days.18 After dental implant surgery, the typical dosing period with APAP/hydrocodone was between 2 and 3 days.40 However, there needs to be flexibility in the number of days supply, because some people will legitimately need analgesics for 6 or 7 days, with 24% in one study still taking analgesics on postoperative day 10 after removal of four third molars.8

![Fig 2. The 95% confidence interval of the number needed to treat (NNT) for at least 50% pain relief over 4 to 6 hours compared with placebo in acute postoperative pain trials.](image-url)

---

**Table:**

<table>
<thead>
<tr>
<th>Analgesic Combination</th>
<th>NNT (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen 200 mg</td>
<td>2.5 (2.0-3.0)</td>
</tr>
<tr>
<td>Ibuprofen 400 mg</td>
<td>2.5 (2.0-3.0)</td>
</tr>
<tr>
<td>Ibuprofen 600 mg</td>
<td>2.5 (2.0-3.0)</td>
</tr>
<tr>
<td>Ibuprofen 800 mg</td>
<td>2.5 (2.0-3.0)</td>
</tr>
<tr>
<td>APAP 650 + oxycodone 5 mg</td>
<td>4.3 (3.5-5.1)</td>
</tr>
<tr>
<td>APAP 1000 + oxycodone 10 mg</td>
<td>4.3 (3.5-5.1)</td>
</tr>
<tr>
<td>APAP 800/1000 + codeine 60 mg</td>
<td>4.3 (3.5-5.1)</td>
</tr>
<tr>
<td>Oxycodeine 15 mg</td>
<td>4.3 (3.5-5.1)</td>
</tr>
</tbody>
</table>

*Based on only 1 to 3 studies (each with less than 300 patients)*
The second part of the question—what happens to unused opioids—is an important public health problem because opioid analgesics are commonly diverted, misused, or abused in the United States. The number of prescriptions dispensed in 2008 for opioid/APAP combination drugs containing hydrocodone, oxycodone, propoxyphene, and codeine, were ranked 1st, 25th, 55th, and 70th, respectively, of all prescribed medications in the United States. The National Survey on Drug Use and Health (NSDUH) found that among persons aged 12 or older in 2007 to 2008 who used pain relievers nonmedically (without a prescription) in the past 12 months, 56% got the pain relievers they most recently used from a friend or relative for free. Another 9% bought them from a friend or relative, and 5% took them from a friend or relative without asking. Nearly one fifth (18%) indicated that they got the drugs they most recently used through a prescription from one doctor. In 82% of the instances where non-medical users of prescription pain relievers obtained the drugs from a friend or relative for free, the individuals indicated that their friend or relative had obtained the drugs from just one doctor. Recent data from Utah showed that 72% of respondents who were prescribed an opioid had leftover medication, and 71% of those with leftover medication kept it. This demonstrates the importance that all clinicians—including dentists—prescribe no more than the number of doses needed based on the usual duration of pain severe enough to require opioids for that condition; further research in this area is warranted in order to better guide dentists. In addition, clinicians must counsel patients to dispose of unused medication once the condition has resolved. The Office of National Drug Control Policy guidelines for the disposal of prescription drugs instructs patients not to flush prescription drugs down the toilet or drain unless the label or accompanying patient information specifically instructs them to do so. Patients should take advantage of community prescription drug take-back programs. If such programs are not available, patients can access an online FDA-maintained list of medicines recommended for flushing.

RECOMMENDATIONS FOR ANALGESIC PRESCRIBING FOR ACUTE DENTAL PAIN

After a review of the literature, a flexible analgesic strategy for the management of acute pain developed in 1995 by the American Association of Endodontists was selected by the authors as a template for an updated set of acute dental pain prescribing recommendations. Input from other published guidelines was also incorporated into the present recommendations. The revisions that were made were derived from the review of clinical trial and meta-analysis data in both dental and non-dental acute postoperative pain, together with the recent FDA mandate concerning prescription APAP dosages. The current recommendations are based on procedures that are likely to induce mild, moderate, or severe pain (Figure 3). This therapeutic paradigm for pain management considers NSAIDs as the first line drugs in most cases of postoperative dental pain based on evidence that optimal doses of NSAIDs are superior in efficacy to single-entity opioids, and are at least as efficacious as optimal doses of peripheral/opioid combination drugs. NSAIDs also have a more favorable side-effect profile than agents that contain an opioid. For patients who can tolerate NSAIDs, ibuprofen 200 mg to 400 mg as needed for pain every 4 to 6 hours is the gold standard for mild pain. If this regimen provides inadequate pain relief, or it is anticipated that the patient will have moderate pain, ibuprofen 400 mg to 600 mg around-the-clock every 4 to 6 hours for the first 24 hours is recommended, followed by ibuprofen 400 mg as needed for pain every 4 to 6 hours. If ibuprofen 400 mg to 600 mg provides inadequate pain relief or moderately severe pain is anticipated, ibuprofen 400 mg to 600 mg plus APAP 500 mg every 6 hours is recommended around-the-clock for the first 24 hours. If that is inadequate, or if severe postoperative pain is anticipated, ibuprofen 400 mg to 600 mg plus APAP 650 mg, combined with an opioid equivalent of hydrocodone 10 mg every 6 hours for the first 48 hours is recommended.

For patients in whom NSAID-like drugs are contraindicated, APAP 650 mg to 1,000 mg is the first-line analgesic. If this regimen provides inadequate pain relief, or it is anticipated that the patient will have moderate pain, APAP 650 mg plus hydrocodone 10 mg around the clock every 6 hours for 24 hours is suggested; then APAP 650 mg as needed for pain every 6 hours. If the pain relief is inadequate or severe pain is anticipated, APAP 650 mg and an opioid equivalent to oxycodone 10 mg around the clock every 6 hours for 48 hours is recommended (nuisance side effects should be anticipated in an opioid-naive individual); then APAP 650 mg to 1,000 mg as needed for pain every 6 hours.

Additional considerations are the use of the long-acting local anesthetic, bupivacaine, immediately after the completion of the surgical procedure, to reduce postoperative pain in both the immediate and distant postoperative period; and the use of preemptive NSAIDs to delay the onset of postoperative dental pain.

SPECIAL POPULATIONS

Substance Abuse Disorders

Dentists should routinely at least ask new patients about their history of addiction or substance abuse—however, in the West Virginia survey of dental professionals, 36% of respondents acknowledged not doing so. The NSDUH reported that the rate of current (past-month) illicit drug use among persons aged 12 or older in 2008 was 8%—therefore, it is not unreasonable that dentists should expect to encounter such patients in their practice. Patients with a history of substance abuse include those that are in drug-free recovery, those that are in recovery with adjuvant pharmacotherapy for prevention of relapse, and those that are on current medication.
have active disease—these groups each have unique challenges (eg, how to manage acute pain in a patient on buprenorphine or methadone maintenance therapy). In addition, an estimated 6% to 10% of the population has attended Alcoholics Anonymous at some point—because of this prevalence of alcoholism, it is likely that dentists will be faced with the need to manage acute pain in a recovering alcoholic. Alcoholics may be at greater risk for the hepatotoxic effects of APAP and the ulcerogenic effects of NSAIDs. Dental professionals must learn to recognize these individuals, determine their status in the recovery process, and establish practices to manage their acute pain appropriately.

It is important to consult with such patients’ primary care provider, as well as the addiction treatment provider. Dental professionals should also collaborate with patients’ family members or support network, particularly if it is established that a controlled substance is necessary for their care (eg, have a “trusted other” dispense each dose of medication rather than giving the patient unsupervised control over the medication). It is recommended that patients be encouraged to intensify their involvement in a recovery program before and after dental treatment that may involve surgery or anticipated postoperative pain. Informed consent—including the risk of initiating a relapse—and strict parameters for treatment are essential, and around-the-clock rather than PRN administration of opioids is recommended to provide timely and effective pain relief and reduce the likelihood that inadequate pain relief will be misinterpreted as drug-seeking behavior.

Opioid analgesic tolerance may be problematic in patients enrolled in methadone or buprenorphine maintenance programs. Additional therapy with opioids for anticipated acute pain should always be discussed with their buprenorphine or methadone maintenance therapy prescriber. Alternatively, the addition of an NSAID to a buprenorphine or methadone regimen is also a reasonable option because of the proven additive analgesic effects of combined NSAIDs and opioids.

Because community dentists see patients frequently and develop long-term relationships with them, they are in a unique position for screening in a public health role. In order to be able to direct patients that they identify as in need of substance abuse treatment, they should become familiar with the American Society of Addiction Medicine’s Patient Placement Criteria, and begin to investigate what addiction resources are available in their community.

### Anticipated post-procedural pain:

**MILD PAIN**  
Examples: simple extraction, routine endodontics, scaling/root planing, gingivectomy, frenectomy, subgingival restorative procedures

- Ibuprofen 200 to 400 mg as needed for pain every 4 to 6 hours
- APAP 650 mg to 1000 mg as needed for pain every 6 hours
- Ibuprofen 400 to 600 mg plus APAP 500 mg around-the-clock every 6 hours for 24 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 500 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 650 mg with hydrocodone 10 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours

### MODERATE PAIN**  
Examples: implant surgery, surgical extraction, quadrant periodontal flap surgery with bony recontouring, surgical endodontics

- Ibuprofen 400 to 600 mg around-the-clock every 4 to 6 hours for 24 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 500 mg around-the-clock every 6 hours for 24 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 650 mg with hydrocodone 10 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 650 mg with oxycodone 10 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours

### SEVERE PAIN**  
Examples: partial or full bony impaction surgery, complex implant or periodontal surgery

- Ibuprofen 400 to 600 mg plus APAP 650 mg with hydrocodone 10 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours
- Ibuprofen 400 to 600 mg plus APAP 650 mg with oxycodone 10 mg around-the-clock every 6 hours for 48 hours
- Then Ibuprofen 400 mg as needed for pain every 4 to 6 hours

### ADDITIONAL CONSIDERATIONS

- Daily ibuprofen doses for acute pain should not exceed 2400 mg
- Daily APAP doses should not exceed 4000 mg
- Pre-emptive NSAID analgesia
- Postoperative long-acting local anesthetic

Fig 3. Analgesic prescribing recommendations for acute post-procedural pain.
Renal and Hepatic Disease
Because toxicities associated with peripherally acting analgesics include renal and hepatic disease, caution is indicated when using these agents in patients with a history of such disorders. Hepatotoxicity is extremely rare with proper use of the currently available analgesics and is most often associated with APAP overdose. However, because APAP is so commonly included in OTC and prescription combination formulations, unintentional overdose is often reported. It has been reported that patients aged older than 65 years are at greater risk for acute liver toxicity with prolonged APAP therapy, although this finding may relate primarily to concomitant drug use in this population.

FUTURE RESEARCH AGENDAS IN ACUTE DENTAL PAIN
Research is needed in a number of areas related to the management of acute postoperative pain in the dental setting. Gaps in current pharmacologic knowledge include the efficacy of prescribing analgesics at fixed intervals versus as needed; demographic, behavioral, and genetic factors that potentially predict pain relief efficacy, adverse outcomes, and abuse; the utility of NSAID/APAP combinations in limiting the need for opioid analgesics; and the utility of long-acting local anesthetics to manage postoperative pain. It is also necessary to better understand practice patterns for pain management and analgesic use (both opioid and non-opioid) among general dentists and dental specialists, their perceptions of risk and safety of opioid analgesics, and their awareness about the increasing problem of prescription drug misuse and abuse; and guide these practitioners in optimal and safe prescribing of analgesics for acute pain in all patients.

ACKNOWLEDGMENT
The authors of this article are extremely grateful for the editorial assistance that Angela T. Casey provided throughout the development of this manuscript.

ABOUT THE AUTHORS
Elliot V. Hersh, DMD, MS, PhD
Professor and Division Director of Pharmacology
Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

William T. Kane, DDS, MBA
Private Practice
Dexter, Missouri

Michael G. O’Neil, PharmD
Associate Professor of Pharmacy Practice
Director for the Center of Excellence for the Education and Prevention of Drug Diversion and Substance Abuse
University of Charleston School of Pharmacy
Charleston, West Virginia

George A. Kenna, PhD, RPh
Assistant Professor of Psychiatry
Center for Alcohol and Addiction Studies, Brown University
Providence, Rhode Island

Nathaniel P. Katz, MD
Adjunct Assistant Professor of Anesthesia
Tufts University School of Medicine
Boston, Massachusetts

Stephanie Golubic, DMD, MBE
Orthodontic Resident
University of North Carolina School of Dentistry
Chapel Hill, North Carolina

Paul A. Moore, DMD, PhD, MPH
Professor of Pharmacology and Chair
Department of Dental Anesthesiology, School of Dental Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

REFERENCES
16. FDA Limits Acetaminophen in Prescription Combination Products; Requires Liver Toxicity Warning. 2011. Available at: www.fda.gov/News-


Prescribing Recommendations for the Treatment of Acute Pain in Dentistry

By Elliot V. Hersh, DMD, MS, PhD; William T. Kane, DDS, MBA; Michael G. O’Neil, PharmD; George A. Kenna, PhD, RPH; Nathaniel P. Katz, MD; Stephanie Golubic, DMD, MBE; and Paul A. Moore, DMD, PhD, MPH

This article provides 2 hours of CE credit from AEGIS Publications, LLC. Record your answers on the enclosed answer sheet or submit them on a separate sheet of paper. You may also phone your answers in to (215) 504-1275 x 207 or fax them to (215) 504-1502 or log on to www.dentalaegis.com/cced and click on “Continuing Education.” Be sure to include your name, address, telephone number, and last 4 digits of your Social Security number.

1. APAP and aspirin have linear dose-response curves with a ceiling effect thought to be in the neighborhood of:
   A. 325 mg.
   B. 650 mg.
   C. 1,000 mg.
   D. 4,000 mg.

2. The maximum recommended daily dose of APAP and aspirin should not exceed:
   A. 1,000 mg.
   B. 2,400 mg.
   C. 4,000 mg.
   D. 6,000 mg.

3. In the United States, the current gold-standard analgesic in moderate to severe postoperative dental pain is:
   A. ibuprofen 400 mg.
   B. APAP 325 mg.
   C. APAP 650 mg.
   D. aspirin 650 mg.

4. Studies have demonstrated that preoperative administration of ibuprofen:
   A. delays the onset of pain by more than 100 minutes compared with placebo.
   B. lessened the severity of postoperative dental pain as the effect of the local anesthetic declined.
   C. lessened the severity of postoperative dental pain without increased side effects.
   D. all of the above.

5. The number of patients with moderate or severe pain achieving at least 50% maximum pain relief over 4 to 6 hours was used to calculate the number needed to treat (NNT) with active drug to get how many additional patients with at least 50% pain relief compared with placebo?
   A. one
   B. 10
   C. 100
   D. 1,000

6. The National Survey on Drug Use and Health (NSDUH) found that among persons aged 12 or older in 2007 to 2008 who used pain relievers non-medically (without a prescription) in the past 12 months, how many got the pain relievers they most recently used from a friend or relative for free?
   A. 9%
   B. 18%
   C. 56%
   D. 82%

7. For patients in whom NSAID-like drugs are contraindicated, what is the first-line analgesic for mild pain?
   A. ibuprofen 200 mg to 400 mg
   B. APAP 650 mg to 1,000 mg
   C. ibuprofen 400 mg to 600 mg plus APAP 1,000 mg
   D. APAP 1,000 mg plus hydrocodone 10 mg

8. The NSDUH reported that the rate of current (past-month) illicit drug use among persons aged 12 or older in 2008 was:
   A. 8%.
   B. 18%.
   C. 28%.
   D. 38%.

9. What estimated percentage of the population has attended Alcoholics Anonymous at some point?
   A. 1% to 4%
   B. 6% to 10%
   C. 14% to 17%
   D. 27% to 31%

10. Because APAP is commonly included in OTC and prescription combination products, their concomitant use can increase the risk of overdose accompanied by:
    A. allergic reactions.
    B. GI ulcers.
    C. hepatotoxicity.
    D. increased intraocular pressure.

The deadline for submission of quizzes is 24 months after the date of publication. Participants must attain a score of 70% on each quiz to receive credit. Participants receiving a failing grade on any exam will be notified and permitted to take one re-examination. Participants will receive an annual report documenting their accumulated credits, and are urged to contact their own state registry boards for special CE requirements.